THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) (a) No, Sir.

(b) Expenditure for 1987-88 in Delhi was Rs. 19,550/- as against Rs. 33,350/- for 1986-87.

Liability on account of unintended benefit

3286. SHRI JASWANT SINGH:

SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 641 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the basis of arriving at the liability of Pifizer at Rs. 99.08 lakhs originally and subsequently revising it to Rs. 48.21 lakhs;

(b) what were the drugs involved and what was the liability in respect of bulk and formulations separately;

(c) what were the names of the formulations which were ignored for the purpose of determining the liability and what were the reasons for such exclusion;

(d) what was the production of each salt of Oxytetracycline and PAS Sodium and other salts separately from the date of filling the writ upto 31-12-83; and

(e) what were the notified prices and the prices availed by the company during the period?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The liability of M/s Pfizer Ltd., was revised to Rs. 48.21 lakhs by the special team taking into account the under charged prices by the company during April-Nov. 1981.

(b) to (e) The details of drugs of its formulations, its production etc. are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

Sub committee on identification of drugs in category II

@3287. SHRI B. SATYANARAYAN REDDY:

SHRI DAYANAND SAHAY:

Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 56 given in the Rajya Sabha on the 27th July, 1988 and state:

(a) whether it is a fact that for the purpose of identifying category II drugs a separate committee was constituted and that recommendations of Ministry of Health and Family Welfare were not sought on the essentiality of the drugs in list II;

(b) whether it is a fact that list of category II drugs, drawn up by the Kelkar Committee abounds in non-essential drugs and also drugs which have marginal sale; and

(c) whether the Ministry of Health and Family Welfare propose to review the conduct of the Officers connected with sending recommendations in respect of category II drugs and shifting of category I to category II and withdraw the recommendations?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) For the purpose of identifying category II drugs a Committee was constituted and the Committee included 2 representatives of the Ministry of Health & Family Welfare.

(b) No, Sir.

(c) Information shall be collected from the Ministry of Health and laid on the Table of the House.

Price control on Isoxuprine HCL range formulations

3288. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 661 given in the Rajya Sabha on the 2nd May, 1988 and state:

@Previously unstarred question 2724, transferred from the 17th August, 1988.